Evidence map›Paper›PMID 38994625›Full record

ArticleCurrent pharmaceutical biotechnology2025

Rawan Alshamy, Nefertiti El-Nikhely, Hisham Nematalla, Mohamed Elkewedi, Eman Abdallah Mahran, Hesham Saeed

Abstract read
PubMed Publisher
In one paragraph

Article in Current pharmaceutical biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rawan AlshamyDepartment of Biotechnology, Institute of Graduate Studies and Research, Alexandria University, Alexandria, Egypt.
Nefertiti El-NikhelyDepartment of Biotechnology, Institute of Graduate Studies and Research, Alexandria University, Alexandria, Egypt.
Hisham NematallaDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Damanhur University, Damanhur, Egypt.
Mohamed ElkewediDepartment of Medical Laboratory Technology, Faculty of Applied Health Sciences Technology, Pharos University in Alexandria, Alexandria, Egypt.
Eman Abdallah MahranDepartment of Biotechnology, Institute of Graduate Studies and Research, Alexandria University, Alexandria, Egypt.
Hesham SaeedDepartment of Biotechnology, Institute of Graduate Studies and Research, Alexandria University, Alexandria, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMicrobial L-asparaginase (L-ASNase, EC 3.5.1.1) is a pivotal biopharmaceutical drug-protein that catalyzes the hydrolysis of the non-essential amino acid L-asparagine (L-Asn) into L-aspartic acid (L-Asp) and ammonia , resulting in deplenishing the cellular L-Asn pool, which leads to the ultimate death of the L-asparagine synthetase (L-ASNS) deficient cancerous cells.

objectiveThis study aimed to investigate the impact of conjugating low molecular weight polyethylene glycol to recombinant

methodsThe recombinant

resultsThe Km and Vmax values of free

conclusionFor the first time, recombinant L-ASNase was modified by covalently attaching PEG (330 Da). The resultant novel proposed PEGylated rL-ASNase with remarkably increased stability and prolonged

Indexed as

AsparaginasePolyethylene GlycolsPseudomonas aeruginosaAnimalsEnzyme StabilityHalf-LifeMaleMolecular Dynamics SimulationMolecular WeightRatsRecombinant ProteinsAsparaginasePolyethylene GlycolsRecombinant Proteinsbio-better.immunogenicityL-asparaginasemolecular dockingmolecular dynamic simulationPEGylationpharmacokinetics

Identifiers

PMID38994625

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.